Literature DB >> 18215781

Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease.

Hildegard T Greinix1, David Pohlreich, Michal Kouba, Ulrike Körmöczi, Imke Lohmann, Karin Feldmann, Christoph Zielinski, Winfried F Pickl.   

Abstract

Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT) and a leading cause of non-relapse mortality (NRM). Currently, biology-based markers are lacking both for diagnosis and for monitoring the activity of cGVHD. Seventy patients who received HSCT were enrolled in a pilot study, including 21 without cGVHD and 49 with active or resolved cGVHD. Evaluations were comprised of clinical parameters including cGVHD severity and infections. Peripheral blood cells were analyzed by multi-parameter flow cytometry. The CD19+ B cell compartment was further subdivided by staining for surface IgD, CD21 and CD27. No significant differences in absolute B, T, and natural killer (NK) cell numbers were observed between the groups with and without cGVHD. However, elevated numbers (>15% of B lymphocytes) of immature/transitional CD19+/CD21(-) B cells were associated with the occurrence of severe infections (P = .003). Most significantly, all patients with active cGVHD and elevated numbers of CD19+/CD21(-) B lymphocytes experienced severe infections (P = .00016). The numbers of both non-class-switched and class-switched memory B cells were significantly lower in patients with active cGVHD when compared to patients who never experienced cGVHD (P = .002 and P = .001). Perturbation of circulating B lymphocyte compartments may serve as a novel biomarker for monitoring cGVHD activity and its impact on the immune system. A prospective study on unselected patients assessed serially for B cell reconstitution after HSCT is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18215781     DOI: 10.1016/j.bbmt.2007.10.009

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  56 in total

1.  Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Whitney S Washel; Nazmim S Bhuiya; Corey S Cutler; Edwin P Alyea; Vincent T Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

2.  Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.

Authors:  Rudolph Kirk R Schultz; Kevin Scott Baker; Jaap J Boelens; Catherine M Bollard; R Maarten Egeler; Mort Cowan; Ruth Ladenstein; Arjan Lankester; Franco Locatelli; Anita Lawitschka; John E Levine; Mignon Loh; Eneida Nemecek; Charlotte Niemeyer; Vinod K Prasad; Vanderson Rocha; Shalini Shenoy; Brigitte Strahm; Paul Veys; Donna Wall; Peter Bader; Stephan A Grupp; Michael A Pulsipher; Christina Peters
Journal:  Biol Blood Marrow Transplant       Date:  2013-07-21       Impact factor: 5.742

Review 3.  The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.

Authors:  Hong-Gang Ren; Djamilatou Adom; Sophie Paczesny
Journal:  Expert Rev Clin Immunol       Date:  2018-04-19       Impact factor: 4.473

Review 4.  Aberrant B-cell homeostasis in chronic GVHD.

Authors:  Stefanie Sarantopoulos; Jerome Ritz
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

5.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Authors:  Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-30       Impact factor: 5.742

6.  The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.

Authors:  Suzanne van Dorp; Henrike Resemann; Liane te Boome; Floor Pietersma; Debbie van Baarle; Frits Gmelig-Meyling; Roel de Weger; Eefke Petersen; Monique Minnema; Henk Lokhorst; Saskia Ebeling; Scott J P Beijn; Edward F Knol; Marijke van Dijk; Ellen Meijer; Jürgen Kuball
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

7.  Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development.

Authors:  Yuri Fedoriw; T Danielle Samulski; Allison M Deal; Cherie H Dunphy; Andrew Sharf; Thomas C Shea; Jonathan S Serody; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-20       Impact factor: 5.742

Review 8.  Cytokine mediators of chronic graft-versus-host disease.

Authors:  Kelli Pa MacDonald; Bruce R Blazar; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

Review 9.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

10.  An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.

Authors:  Jonathan C Poe; Wei Jia; Hsuan Su; Sarah Anand; Jeremy J Rose; Prasanthi V Tata; Amy N Suthers; Corbin D Jones; Pei Fen Kuan; Benjamin G Vincent; Jonathan S Serody; Mitchell E Horwitz; Vincent T Ho; Steven Z Pavletic; Frances T Hakim; Kouros Owzar; Dadong Zhang; Bruce R Blazar; Christian W Siebel; Nelson J Chao; Ivan Maillard; Stefanie Sarantopoulos
Journal:  Blood       Date:  2017-08-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.